Autopsy report · NCT02693171
Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 9 months before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 2 years 8 months after it ended.
Vital statistics
- Status
- Terminated
- Sponsor
- United Therapeutics
- Sponsor type
- Industry
- Conditions
- Neuroblastoma
- Interventions
- Dinutuximab
- Participants
- 13
- Sites
- 18
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.